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Abstract
Objective—To evaluate relationships between vitamin D, proteinuria, and disease activity in
pediatric systemic lupus erythematosus (SLE) and juvenile dermatomyositis (JDM).
Study design—Multiple linear regression was used to associate subject-reported race, sunscreen
use, and vitamin D intake with physician-assessed disease activity and serum 25-hydroxyvitamin
D [25(OH)D] in subjects with pediatric SLE (n = 37) or JDM (n = 21). Serum 25(OH)D was
correlated with urinary vitamin D binding protein/creatinine ratio (DBP/C) and other indicators of
proteinuria.
Results—Serum 25(OH)D levels in subjects with SLE were inversely associated with the natural
log of urinary DBP/C (r = −0.63, p < 0.001) and urine protein to creatinine ratio (r = −0.60,
p<0.001), with an adjusted mean 10.9 (95% CI 5.1, 16.8) ng/mL decrease in 25(OH)D for those
with proteinuria. Excluding subjects with proteinuria, serum 25(OH)D levels were inversely
associated with disease activity in JDM, but not in SLE. Overall, 66% of all subjects were taking
concurrent corticosteroids, but this was not associated with 25(OH)D levels.
Conclusions—Low serum 25(OH)D in patients with SLE is associated with proteinuria and
urinary DBP. Vitamin D deficiency is associated with disease activity in patients with JDM and
SLE; this relationship in SLE may be confounded by proteinuria.
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Beyond its skeletal effects, vitamin D has been recognized as an immunomodulator with
effects on antigen-presenting cells. Vitamin D deficiency is associated with darker skin tone,
winter season, northern latitude, age, and female sex.1 Low 25-hydroxyvitamin D
[25(OH)D] levels have been associated with increased odds of multiple sclerosis, Crohn’s
disease and rheumatoid arthritis, in retrospective epidemiologic studies.1 Vitamin D
deficiency has also been associated with measures of cardiovascular risk, including body
mass index, hypertension, and hyperglycemia.2 In adults, the optimal level of 25(OH)D for
improved skeletal outcomes has been suggested to be ≥ 30 ng/mL, but it is not yet known
whether this level is optimal for other outcomes.1,3 Optimal levels in children are not well
established. As many as 70% of American children may have 25(OH)D levels <30 ng/mL.4
Hydroxylation of 25(OH)D to the active form, 1,25-dihdroxyvitamin D, occurs in the
kidney, but also locally in cells of the immune system. In vitro, 1,25-dihydroxyvitamin D
prevents differentiation of dendritic cells and modulates T cell phenotype and function.5
1,25-dihydroxyvitamin D may inhibit T cell proliferation and cytokine production, inhibit
proliferation of activated B cells, and impair generation of plasma cells.67 Differentiation of
dendritic cells and the resultant production of type I interferon may be important in the
pathogenesis of systemic lupus erythematosus (SLE).8
Animal models have shown that vitamin D and calcium supplementation can inhibit lupus
activity.9,10 There have been incidental findings of an association between vitamin D
deficiency and SLE nephritis,11 but studies evaluating this relationship are lacking. There
have been no correlations in subjects with SLE between vitamin D status and direct or
indirect measures of proteinuria, such as spot urine protein to creatinine (UP/C) ratio or
serum albumin.
Juvenile dermatomyositis (JDM) is a photosensitive rheumatic disease, treated commonly
with sun avoidance, corticosteroids, methotrexate and hydroxychloroquine. JDM shares
many similarities with pediatric SLE in photosensitivity and methods of treatment, but is not
associated with proteinuria, making this an ideal comparison group for SLE. Studies
specifically evaluating the relationship between vitamin D levels and disease activity in
JDM have not been reported. Given the lack of information on vitamin D status in JDM, we
chose to evaluate serum vitamin D levels and associated risk factors in this population to
increase the information known on vitamin D status in pediatric rheumatic diseases.
The objectives of this prospective cohort study are to determine whether low levels of
25(OH)D are associated with proteinuria and assess the relationship between vitamin D
deficiency and disease activity in two photosensitive autoimmune conditions (SLE and
JDM).
Methods
Children and adolescents with SLE or JDM prior to the age of 18 were eligible. Subjects
were excluded if they were pregnant, were taking bisphosphonates, had received organ
transplantation, or were taking greater than 1,000 IU daily supplemental vitamin D in the
past 3 months. All patients who met these criteria and were seen in the Duke Pediatric
Rheumatology Clinic, Duke Lupus Clinic, or University of North Carolina Pediatric
Nephrology Clinic were prospectively approached for recruitment between May 2009 and
March 2010. The diagnosis of SLE was confirmed using the revised American College of
Rheumatology criteria,12 and JDM was confirmed using Bohan and Peter criteria.13 The
Institutional Review Boards of Duke University Medical Center and the University of North
Carolina at Chapel Hill approved the protocol.
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Informed consent was obtained from the young adults and the parents or guardians of those
younger than 18 years of age, from whom assent was obtained.
Disease and subject characteristics and medication exposures
All SLE or JDM clinical manifestations and medication exposures were documented by
medical record abstraction. Dietary information on vitamin D intake was obtained using an
adult food frequency questionnaire previously validated against 7-day food diaries by
Blalock et al.14 No short validated questionnaires regarding calcium and vitamin D intake
were available for children at the time of this study. Sunscreen usage, vitamin D supplement
intake, and race/ethnicity were obtained by standardized questionnaire. No information was
collected on sun exposure. Doses of vitamin D supplementation were checked against the
medical record by the primary investigator when subjects reported taking supplementation
but could not recall the dose. Disease activity at the time of the study visit was assessed by
the medical provider using a Physician’s Global Assessment (PGA) by 10 cm visual
analogue scale in all subjects and Systemic Lupus Erythematosus Disease Activity Index
(SLEDAI) in subjects with SLE.15
Renal disease
Serum albumin and UP/C ratios were measured at individual institutions. Proteinuria was
defined as a UP/C ratio greater than or equal to 0.5. SLE nephritis was defined by
histopathological pattern on renal biopsy according to the 2003 ISN/RPS classification
system.16 Estimated glomerular filtration rates (eGFR) were calculated based on height and
serum creatinine using the classical Schwartz formula.17
Vitamin D binding protein and vitamin D metabolite analysis
Serum 25(OH)D concentrations were analyzed using tandem mass spectroscopy available
from Mayo Laboratories. Urinary DBP in ng/dL was measured with a vitamin D binding
protein EIA kit (ALPCO Diagnostics, Salem, NH), and standardized against concurrent
urinary creatinine measurements in mg/dL. Urinary vitamin D metabolite content was
measured according to previously published methods.18 The procedure involved
concentration of 10 mL of urine to 3 mL using centriprep-30 concentrators (Amicon Inc,
Beverly, MA). The concentrated samples were subjected to a modified dichloromethane-
methanol liquid-liquid extraction followed by solid-phase separation on silica cartridges.
The first two fractions from the solid phase extraction (containing 25(OH)D and 24,25-
dihydroxyvitamin D) were combined and assayed by radioimmunoassay kits (12% intra-
assay CV) for 25(OH)D (Diasorin, Stillwater, MN). Samples were measured in duplicate.
Statistical analysis
Analyses were performed using STATA 10.0 (StataCorp., College Station, TX). Two-sided
tests of hypotheses were used; p-values less than 0.05 were considered statistically
significant. Differences in means were assessed using Student t-test. Differences in
proportions were assessed using chi-square or Fisher exact test, where appropriate.
Correlation between serum 25(OH)D levels and urinary DBP/C was obtained using pair-
wise correlation. Multivariable linear regression was used to determine differences in
25(OH)D levels in subjects with and without proteinuria, adjusting for disease type, race,
disease activity, sunscreen usage, and dietary/supplement intake.
Results
There were 58 subjects age 4 to 21 years included in our study; 21 subjects with JDM and
37 subjects with SLE. Demographic and baseline characteristics of disease activity are
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provided in Table I. There was no significant difference in prevalence of obesity, mean
prednisone dose, percentage taking hydroxychloroquine, percentage using sunscreen
regularly, intake of vitamin D supplements, or dietary intake of vitamin D between patients
with SLE and JDM.
Among those with SLE, all subjects with proteinuria had documented renal biopsies with
glomerulonephritis between class III and V. Roughly half of subjects with SLE without
proteinuria had a history of proliferative nephritis. Three subjects with proteinuria had
estimated glomerular filtration rates below 75 ml/min/1.73 m2. Subjects with proteinuria had
lower serum albumin levels.
Serum 25(OH)D, proteinuria, and urinary DBP/C
Serum 25(OH)D levels indicated high prevalence of levels below 30 ng/mL among all three
groups; proteinuria was associated with a mean 13 ng/mL decrease in vitamin D level
among subjects with SLE (Table I). Subjects with proteinuria had 19.7 times increased odds
of levels ≤10 ng/mL (95% CI 1.8 to 944.5). Serum 25(OH)D levels in subjects with SLE
were inversely associated with the UP/C ratio (r = −0.67, p < 0.001) and urinary DBP/C (r =
−0.59, p < 0.001) and directly associated with serum albumin (Figure). Serum 25(OH)D
levels in subjects with JDM were not associated with UP/C ratio, urinary DBP/C, or serum
albumin. Pair wise association and linear regression using the natural log of the UP/C and
DBP/C ratios improved model fit, but did not change the interpretation. (Figure and Table
II). Urinary DBP/C and 25(OH)D/C values were highly variable, although mean DBP/C was
highest in the urine of subjects with SLE and proteinuria. (Table I). Vitamin D metabolite
content in the urine of subjects with SLE and proteinuria tended to be either high or very
low.
Evaluation of vitamin D by risk factors
Using analysis of variance or simple regression, vitamin D status was not associated with
age, obesity, dietary intake of vitamin D, history of photosensitivity, current rash, or
duration of disease. Higher serum 25(OH)D levels were associated with white race, JDM
compared with SLE, and lower disease activity by PGA. Vitamin D supplementation (800
IU daily) was associated with a mean 10.0 (95% CI 3.2, 16.8) ng/mL increase in 25(OH)D
level compared with non-supplementation. Regular use of sunscreen was associated with a 6
ng/mL increase in 25(OH)D, although regular sunscreen users were also more likely to take
vitamin D supplements.
Among subjects with SLE, lower vitamin D status was significantly associated with
increased SLEDAI, PGA, and presence of class III or higher glomerulonephritis. Because all
subjects with severe vitamin D deficiency had renal disease, an odds ratio for renal disease
and severe vitamin D deficiency could not be calculated.
Multivariate analysis
Among subjects with SLE, after adjusting for white race and use of supplements, disease
activity by PGA or SLEDAI and proteinuria were all independently and inversely associated
with serum 25(OH)D levels (Table II and Figure). There did not appear to be any significant
interaction between proteinuria and race, use of supplements, or disease activity. There was
co-linearity between the presence of proteinuria and increasing PGA and SLEDAI. When
subjects with proteinuria were excluded, increased PGA and SLEDAI were no longer
associated with decreased serum 25(OH)D levels. In these models, proteinuria was
associated with a 10.9 ng/mL (95% CI 5.1 to 16.8 ng/mL) decrease in vitamin D level.
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After adjusting for known influences on vitamin D status (race and use of vitamin D
supplements), increasing disease activity by PGA was associated with decreasing 25(OH)D
levels among subjects with JDM. Current active rash was not significantly associated with
serum 25(OH)D levels in these subjects. For subjects with JDM, each 400 IU of daily
vitamin D supplementation was associated with a mean increase in 25(OH)D of 6.5 ng/mL
(95% CI 1.3 to 11.7). Each 1 cm increase in PGA was associated with a mean decrease in
serum 25(OH)D of 1.7 ng/mL (95% CI 0.3 to 3.1 ng/mL). Increased prednisone dosage was
not associated with vitamin D levels after adjustment for race and vitamin D
supplementation.
Discussion
We demonstrate here an inverse relationship between serum 25(OH)D levels and proteinuria
in subjects with SLE. Several studies have shown high rates of vitamin D deficiency in
subjects with SLE, associated with measures of disease activity (including renal disease) and
cardiovascular risk.11,19,20,21,22 In a prior retrospective chart review of subjects with
pediatric SLE at our institution, we reported an association between proliferative SLE
glomerulonephritis and vitamin D deficiency (OR 11.7, 95% CI 1.5, 89.3), and an average
10 ng/mL difference in serum 25(OH)D between subjects with and without nephritis.23 We
did not have statistical power to adjust for possible confounding factors. We suggest that
previously reported associations between measures of disease activity and vitamin D status
in SLE may be confounded by an unrecognized association between proteinuria and
increased disease activity.
Serum 25(OH)D levels in subjects with JDM appear to be associated with disease activity
and to be similar to that of subjects with SLE without proteinuria. One prior study has
reported no significant difference in 25(OH)D levels among children with high and low
disease activity in JDM; however, this was a subgroup of a larger study and was
underpowered for subgroup analysis (n = 13).24 There was a mean 7 ng/mL decrease in
25(OH)D among children with high disease activity; however, this was not statistically
significant.
Prior studies have associated proteinuria and nephrotic syndrome with 25(OH)D deficiency,
regardless of renal insufficiency.25,26,27,28,29 Urinary losses of 25(OH)D and vitamin D
binding protein (DBP) in the urine, by competitive binding assay, in patients and animals
with nephritic syndrome have been reported.28,30,31 Despite this, urinary loss of vitamin D is
not well recognized as a potential explanation for vitamin D deficiency.
Thierry-Palmer et al have demonstrated vitamin D metabolites and vitamin D binding
activity in the urine of normal female black and white adolescents.18 The findings in this
study of an inverse relationship between serum 25(OH)D levels and urinary DBP/C and the
negative correlation between serum 25(OH)D levels and UP/C suggest loss of protein-bound
vitamin D metabolites as one factor for low vitamin D status in pediatric lupus patients. It is
possible that part of the vitamin D deficiency associated with lupus activity may be
confounded by an underlying association between proteinuria and low 25(OH)D levels as
well as proteinuria and increasing measures of disease activity. In the SLE disease activity
index, proteinuria, hematuria, and active renal sediment each account for 4 points on the
activity score.
The DBP-25(OH)D complex is filtered through the proximal tubule cells of the kidney,
where it is reabsorbed by an endocytic process governed by two carrier proteins, cubilin and
megalin.32,33,34 Megalin antibodies (anti-LRP2) have been described in patients with SLE
and other rheumatic diseases,35 and megalin knockout mice exhibit low molecular weight
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proteinuria and severe vitamin D deficiency.36 DBP itself is genetically similar to albumin
and highly complexed to 25(OH)D. Loss of DBP can decrease the half-life of 25(OH)D in
serum.37 In this study, the high or very low 25(OH)D content in urine of subjects with
proteinuria may be explained by urinary 25(OH)D content being dependent on both urinary
DBP and on serum 25(OH)D. Low serum 25(OH)D levels would decrease the amount of
25(OH)D bound to the DBP that is spilled into urine. In a previous study, urinary 25(OH)D
levels did not correlate well with urinary vitamin D binding activity (indicative of urinary
DBP) of healthy adolescent girls.18 DBP loss into urine may simply reflect the magnitude of
proteinuria exhibited by these patients, but it is not known whether anti-megalin antibodies,
leading to DBP loss and low vitamin D levels, play a part in the pathogenesis of renal
disease in patients with SLE. More studies are needed on the relationship between megalin,
megalin antibodies, and urinary DBP in subjects with SLE and other proteinuric diseases.
Supplementation with vitamin D at currently recommended levels (400 IU/day) increased
the mean serum 25(OH)D level, but many subjects had low vitamin D levels despite
supplementation. We suspect that much higher levels of vitamin D supplementation are
required to maintain optimal serum 25(OH)D levels, especially in those patients with
proteinuria or active disease. It is unknown what effect vitamin D deficiency has on
cardiovascular risk and skeletal outcomes in these patients, although vitamin D deficiency in
healthy individuals and adults with SLE have been associated with increasing cardiovascular
risk.
There are several limitations of this study. We were unable to adjust for season because this
study took place over 10 months of recruitment. We did not have sufficient power to
examine risk factors which may have had a more subtle impact on vitamin D levels – body
mass index, sunscreen use and vitamin D dietary intake. Nevertheless, from estimation of
dietary levels of vitamin D intake by food frequency questionnaire, most of our subjects do
not eat sufficient quantities of vitamin D-containing foods to ensure adequate intake of
vitamin D. Although there were three subjects with eGFR below 75 ml/min/1.73 m2
(between 50 and 60 ml/min/1.73 m2), lower eGFR levels were not associated with lower
levels of serum 25(OH)D in this cohort. Impaired renal function is known to affect
hydroxylation of 25(OH)D to 1,25-dihydroxyvitamin D, but should not impact the serum
levels of 25(OH)D.
A strength of this study is an enriched sample of subjects with renal disease, allowing for a
closer look at the relationship between proteinuria and vitamin D deficiency. This study was
also strengthened by information on dietary history and sunscreen usage in subjects with
rheumatic disease, multiple assessments of disease activity in subjects with SLE, and
multiple assessments of proteinuria and renal disease (spot urine protein to creatinine ratio,
serum albumin, urinary DBP, and renal biopsy information).
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List of abbreviations
SLE systemic lupus erythematosus
JDM juvenile dermatomyositis
25(OH)D 25-hydroxyvitamin D
DBP/C urinary vitamin D binding protein/creatinine ratio
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UP/C spot urine protein to creatinine
eGFR estimated glomerular filtration rates
SLEDAI Systemic Lupus Erythematosus Disease Activity Index
PGA Physician’s Global Assessment
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Greater proteinuria and lower albumin are associated with vitamin D deficiency among
subjects with SLE even with adjustment for race and vitamin D supplementation. A) Serum
25(OH)D level by log-transformation of spot urine protein to creatinine ratio among subjects
with SLE* B) Serum 25(OH)D level by serum albumin among subjects with SLE** C)
Serum 25(OH)D level by log transformation of urinary DBP / urinary creatinine among
subjects with SLE***.
* n = 36, β = −4.8 (95% CI −6.6, −3.0), adjusted β = −4.1 (−6.0, −2.2)
** n = 37, β = 7.0 (95% CI 3.4, 10.7), adjusted β = 5.9 (95% CI 2.1, 9.6)
*** n = 34 β = −5.4 (95% CI −7.7, −3.0), adjusted β = −4.6 (95% CI −7.1, −2.2)
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Age, y (mean, SD)* 15.4 (3.8) 14.5 (4.6) 11.3 (4.1)
   Range 6 to 21 5 to 20 4 to 18
Duration of disease, y 2.5 (2.7) 3.5 (3.8) 3.3 (3.5)
   Range 0 to 12 0 to 12 0 to 12
Sex (% female) 88 69 81
Race*
   White 4 (17%) 1 (8%) 16 (76%)
   Black 18 (75%) 9 (69%) 3 (14%)
   Other/Mixed 2 (8%) 3 (23%) 2 (10%)
BMI percentile ≥ 85 (%) 50 54 33
Initial PGA, cm* 1.1 (1.0) 4.7 (2.8) 2.2 (3.1)
   Range 0 to 3.7 0 to 8.9 0 to 8.3
Initial SLEDAI* 4.9 (4.3) 15.0 (7.8) N/A
   Range 0 to 16 4 to 28
Glomerulonephritis
   III 3 (13%) 2 (15%) N/A
   IV 3 (13%) 4 (31%)
   V 4 (17%) 2 (15%)
   III and IV 0 1 (8%)
   III and V 1 (4%) 3 (23%)
   IV and V 0 1 (8%)
Serum albumin (g/dL)* 3.8 (0.5) 2.9 (0.9) 4.1 (0.4)
   Range 2.1 to 4.7 1.1 to 4.4 2.8 to 4.7
Serum creatinine (mg/dL)* 0.7 (0.2) 0.8 (0.5) 0.5 (0.2)
   Range 0.2 to 1.0 0.3 to 1.7 0.3 to 0.9
Estimated glomerular filtration rate 143 (49) 140 (77) 169 (49)
(ml/min/1.73 m2) 81 to 323 52 to 312 104 to 297
History of photosensitivity (%)* 71 46 90
Active rash (%)* 25 23 57
Mean prednisone dose (mg/d) 13 (15) 23 (25) 17 (27)























Plaquenil (% taking) 92 69 76
Uses sunscreen every day or most days (%) 70 31 62
Mean dietary intake of vitamin D (IU/day) 104 150 115
Vitamin D supplementation
   None 11 (48%) 10 (77%) 14 (67%)
   400 IU/day 6 (26%) 2 (15%) 3 (14%)
   800 IU/day 6 (26%) 1 (8%) 4 (19%)
Serum 25(OH)D status*
   Mean, SD (ng/mL) 25.0 (9.2) 11.9 (5.6) 26.2 (11.0)
   ≤ 10 ng/mL 1 (4%) 6 (46%) 1 (5%)
   10.1–20 ng/mL 6 (25%) 5 (39%) 6 (29%)
   20.1–30 ng/mL 11 (46%) 2 (15%) 7 (33%)
   >30 ng/mL 6 (25%) 0 (0%) 7 (33%)
Urinary DBP/C, ng/mg (mean, SD)* 13 (17) 33 (27) 15 (14)
Urinary 25(OH)D/C, pg/mg (mean, SD) 6 (5) 6 (10) 6 (6)
*
P < 0.05 for differences between 3 groups by ANOVA. All other comparisons were not significant
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